Shares of American Renal Associates Holdings Inc. (NYSE:ARA) were up 3.4% during mid-day trading on Monday . The company traded as high as $20.65 and last traded at $20.49, with a volume of 60,688 shares. The stock had previously closed at $19.81.

A number of analysts recently issued reports on ARA shares. SunTrust Banks Inc. started coverage on shares of American Renal Associates Holdings in a research report on Monday, May 16th. They set a “buy” rating and a $34.00 target price for the company. Zacks Investment Research raised shares of American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a research report on Monday, July 18th. Leerink Swann reaffirmed a “buy” rating on shares of American Renal Associates Holdings in a research report on Thursday, August 11th. Barclays PLC reaffirmed a “buy” rating and issued a $31.00 price objective on shares of American Renal Associates Holdings in a research report on Thursday. Finally, Bank of America Corp. reaffirmed a “buy” rating and issued a $35.00 price objective on shares of American Renal Associates Holdings in a research report on Monday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $31.17.

The firm’s market capitalization is $627.55 million. The company’s 50-day moving average is $0.00 and its 200-day moving average is $0.00.

American Renal Associates Holdings (NYSE:ARA) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.75) EPS for the quarter. The business earned $185.60 million during the quarter, compared to analysts’ expectations of $161.50 million. On average, equities analysts anticipate that American Renal Associates Holdings Inc. will post $0.96 earnings per share for the current year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.